BRPI0418306B8 - composto n-[(1s,1ar,7br)-4,7-difluoro-1,1a,2,7b-tetraidrociclopropa[c]cromen-1-il]-n-[5-(4-(sulfonamido)fenoxi)-2-piridinil]ureia, composição farmacêutica e uso do dito composto para profilaxia ou tratamento de infecções por hiv-1 - Google Patents
composto n-[(1s,1ar,7br)-4,7-difluoro-1,1a,2,7b-tetraidrociclopropa[c]cromen-1-il]-n-[5-(4-(sulfonamido)fenoxi)-2-piridinil]ureia, composição farmacêutica e uso do dito composto para profilaxia ou tratamento de infecções por hiv-1Info
- Publication number
- BRPI0418306B8 BRPI0418306B8 BRPI0418306A BRPI0418306A BRPI0418306B8 BR PI0418306 B8 BRPI0418306 B8 BR PI0418306B8 BR PI0418306 A BRPI0418306 A BR PI0418306A BR PI0418306 A BRPI0418306 A BR PI0418306A BR PI0418306 B8 BRPI0418306 B8 BR PI0418306B8
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- compound
- orx
- nrxrx
- hiv
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000031886 HIV Infections Diseases 0.000 title 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
- 239000004202 carbamide Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 abstract 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 abstract 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 229940121357 antivirals Drugs 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000002170 ethers Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
inibidores de transcriptase reserva não nucleotídicos compostos de fórmula z: (z) onde; a é ch ou n; r1 é um sustituinte para um átomo de carbono no anel contendo a selecionado de -s(=o) pra, onde ra é -alquil c1-c4- orx, -nrxrx, -nhnrxrx, -nhnhc (=o) orx, -nrxoh; -c(=o) -rb, onde rb é -alquil c1-c4-, -orx -nrxrx, -nhnrxrx, -nh-alquil c1-c3-c (=o) orx, -nrxrc, onde rc é h, alquil c1-c4, -nrxrx; -c(=o) rd, -cn, s (=o) prx onde rd é rd é alquil c1-c4, -orx, -nrxrx, -alquil c1-c3-o-alquil c1-c3-c (=o) orx, -alquil c1-c3-coorx; éteres ou ésteres -alquil c1-c3-oh ou alquil c1-c4 dos mesmos -(o-alquil c1-c3) q-o-rx; um anel aromático de 5 ou 6 membros tendo de 1-3 heteroátomos; p é 1 ou 2; rx é independentemente selecionado de h, alquil c1-c4 ou acetil; ou um par de rx que pode junto com o átomo de n adjacente formar um anel; l é -o-, -s(=o)r- ou -ch2-, onde r é 0, 1 ou 2; r3-r7 são substituintes como definido na especificiação; x é - (cr8r'8) n-d- (cr8r8) m-; d é uma ligação, -nr9-, -o-, -s-, -s(=o) - ou -s(=o)2-; e sais farmaceuticamente aceitáveis e pró-fármacos dos mesmos, tendo utilidade como anti-virais para hiv.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0400021A SE0400021D0 (sv) | 2004-01-08 | 2004-01-08 | Non-nucleoside reverse transcriptase inhibitors |
| SE0400585A SE0400585D0 (sv) | 2004-03-09 | 2004-03-09 | NNRTI Antivirals |
| PCT/SE2004/002034 WO2005066131A1 (en) | 2004-01-08 | 2004-12-30 | Non-nucleotide reverse transcriptase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0418306A BRPI0418306A (pt) | 2007-05-02 |
| BRPI0418306B1 BRPI0418306B1 (pt) | 2018-09-18 |
| BRPI0418306B8 true BRPI0418306B8 (pt) | 2021-05-25 |
Family
ID=34752289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0418306A BRPI0418306B8 (pt) | 2004-01-08 | 2004-12-30 | composto n-[(1s,1ar,7br)-4,7-difluoro-1,1a,2,7b-tetraidrociclopropa[c]cromen-1-il]-n-[5-(4-(sulfonamido)fenoxi)-2-piridinil]ureia, composição farmacêutica e uso do dito composto para profilaxia ou tratamento de infecções por hiv-1 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7915295B2 (pt) |
| EP (1) | EP1701942B1 (pt) |
| JP (1) | JP4762917B2 (pt) |
| AT (1) | ATE451357T1 (pt) |
| AU (1) | AU2004312284B2 (pt) |
| BR (1) | BRPI0418306B8 (pt) |
| CA (1) | CA2550187C (pt) |
| DE (1) | DE602004024584D1 (pt) |
| DK (1) | DK1701942T3 (pt) |
| EA (1) | EA009700B1 (pt) |
| ES (1) | ES2337794T3 (pt) |
| HK (1) | HK1101400A1 (pt) |
| IL (1) | IL176740A (pt) |
| NZ (1) | NZ548367A (pt) |
| SG (1) | SG149070A1 (pt) |
| WO (1) | WO2005066131A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1534276B1 (en) * | 2002-09-05 | 2008-11-05 | Medivir AB | Non-nucleoside reverse transcriptase inhibitors |
| US7388008B2 (en) | 2004-08-02 | 2008-06-17 | Ambrilia Biopharma Inc. | Lysine based compounds |
| ES2539527T3 (es) * | 2005-04-27 | 2015-07-01 | Taimed Biologics, Inc. | Método para mejorar la farmacocinética de los inhibidores de las proteasas y de los precursores de los inhibidores de las proteasas |
| EP1971615B1 (en) | 2005-11-30 | 2014-01-01 | TaiMed Biologics, Inc. | Lysme-based prodrugs of aspartyl protease inhibitors and processes for their preparation |
| GB0608876D0 (en) * | 2006-05-05 | 2006-06-14 | Medivir Ab | Combination therapy |
| EP2021327B1 (en) * | 2006-05-15 | 2012-04-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2008078200A2 (en) | 2006-09-21 | 2008-07-03 | Ambrilia Biopharma Inc. | Protease inhibitors |
| JP6636031B2 (ja) * | 2015-01-30 | 2020-01-29 | ジェネンテック， インコーポレイテッド | 治療用化合物およびその使用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200002058T2 (tr) * | 1998-01-16 | 2001-05-21 | Medivir Ab | Antiviraller |
| WO1999051613A1 (en) * | 1998-04-03 | 1999-10-14 | Medivir Ab | Prodrugs of phosphorous-containing pharmaceuticals |
| SE0100733D0 (sv) * | 2001-03-05 | 2001-03-05 | Medivir Ab | Non-nucleoside reverse transcriptase inhibitors |
| SE0102867D0 (sv) * | 2001-08-28 | 2001-08-28 | Medivir Ab | Non-nucleoside reverse transcriptase inhibitors |
| EP1534276B1 (en) * | 2002-09-05 | 2008-11-05 | Medivir AB | Non-nucleoside reverse transcriptase inhibitors |
-
2004
- 2004-12-30 AU AU2004312284A patent/AU2004312284B2/en not_active Ceased
- 2004-12-30 DK DK04809207.6T patent/DK1701942T3/da active
- 2004-12-30 JP JP2006549182A patent/JP4762917B2/ja not_active Expired - Fee Related
- 2004-12-30 ES ES04809207T patent/ES2337794T3/es active Active
- 2004-12-30 WO PCT/SE2004/002034 patent/WO2005066131A1/en active Application Filing
- 2004-12-30 SG SG200809639-8A patent/SG149070A1/en unknown
- 2004-12-30 NZ NZ548367A patent/NZ548367A/en not_active IP Right Cessation
- 2004-12-30 BR BRPI0418306A patent/BRPI0418306B8/pt not_active IP Right Cessation
- 2004-12-30 US US10/584,933 patent/US7915295B2/en not_active Expired - Fee Related
- 2004-12-30 AT AT04809207T patent/ATE451357T1/de not_active IP Right Cessation
- 2004-12-30 DE DE602004024584T patent/DE602004024584D1/de active Active
- 2004-12-30 EA EA200601289A patent/EA009700B1/ru not_active IP Right Cessation
- 2004-12-30 CA CA2550187A patent/CA2550187C/en not_active Expired - Fee Related
- 2004-12-30 EP EP04809207A patent/EP1701942B1/en active Active
-
2006
- 2006-07-06 IL IL176740A patent/IL176740A/en not_active IP Right Cessation
-
2007
- 2007-08-29 HK HK07109407.1A patent/HK1101400A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK1701942T3 (da) | 2010-04-06 |
| NZ548367A (en) | 2010-06-25 |
| EP1701942A1 (en) | 2006-09-20 |
| SG149070A1 (en) | 2009-01-29 |
| ES2337794T3 (es) | 2010-04-29 |
| HK1101400A1 (en) | 2007-10-18 |
| AU2004312284A1 (en) | 2005-07-21 |
| BRPI0418306B1 (pt) | 2018-09-18 |
| IL176740A0 (en) | 2006-10-31 |
| DE602004024584D1 (de) | 2010-01-21 |
| JP4762917B2 (ja) | 2011-08-31 |
| BRPI0418306A (pt) | 2007-05-02 |
| EA009700B1 (ru) | 2008-02-28 |
| AU2004312284A2 (en) | 2005-07-21 |
| CA2550187C (en) | 2012-08-07 |
| AU2004312284B2 (en) | 2010-08-05 |
| JP2007519640A (ja) | 2007-07-19 |
| US20080070951A1 (en) | 2008-03-20 |
| WO2005066131A1 (en) | 2005-07-21 |
| EP1701942B1 (en) | 2009-12-09 |
| EA200601289A1 (ru) | 2006-12-29 |
| CA2550187A1 (en) | 2005-07-21 |
| ATE451357T1 (de) | 2009-12-15 |
| IL176740A (en) | 2011-09-27 |
| US7915295B2 (en) | 2011-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
| MA54327B1 (fr) | Inhibiteurs de kras g12c | |
| AR062109A1 (es) | Derivados sustituidos de espirocetal y uso de los mismos como farmacos terapeuticos para la diabetes. composiciones farmaceuticas. | |
| EA200970461A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| JP2007533741A5 (ja) | Ｂａｃｅ阻害剤として有用なピロリジン誘導体 | |
| JP2013531029A5 (pt) | ||
| EA201791254A1 (ru) | Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета | |
| GEP20156250B (en) | 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 | |
| NO20070258L (no) | Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer | |
| MA33240B1 (fr) | Inhibiteurs de bêta-sécrétase | |
| NO20065613L (no) | 3-karbamoyl-2-pyridonderivat. | |
| DK1119567T3 (da) | Quinazolinderivater | |
| RU2010126105A (ru) | Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой, и содержащие их противогрибковые средства | |
| DE602005016297D1 (de) | Antithrombotische diamide | |
| AR069789A1 (es) | Pirazoles condensados, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento del sida o el arc. | |
| EA200900135A1 (ru) | Производные пиразола в качестве ингибиторов цитохрома р450 | |
| EA201000702A1 (ru) | Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы | |
| RU2012137501A (ru) | Сигма-лиганды для применения при профилактике и/или лечении послеоперационной боли | |
| EA200501075A1 (ru) | Лекарственное средство для профилактики и лечения артериосклероза и гипертензии | |
| BRPI0418306B8 (pt) | composto n-[(1s,1ar,7br)-4,7-difluoro-1,1a,2,7b-tetraidrociclopropa[c]cromen-1-il]-n-[5-(4-(sulfonamido)fenoxi)-2-piridinil]ureia, composição farmacêutica e uso do dito composto para profilaxia ou tratamento de infecções por hiv-1 | |
| RU2012106822A (ru) | Индольное производное или его фармацевтически приемлемая соль | |
| JP2005503435A5 (pt) | ||
| RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| ATE308540T1 (de) | Antithrombosemittel | |
| WO2005100322A8 (en) | Sulphur-linked imidazole compounds for the treament of hiv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/09/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 17A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2651 DE 26-10-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |